https://doi.org/10.55788/e7e6b145
ILD is identified in most patients with SSc and is the leading cause of SSc-related mortality [1]. HRCT is the gold standard for diagnosis. However, some physicians do not regularly perform baseline HRCTs in all patients. “Our previous survey identified that only about 66% of physicians regularly screen for ILD with HRCT at the time of SSc diagnosis, and this percentage drastically drops to less than 15% during follow-up visits,” explained Dr Cosimo Bruni (University of Zürich, Switzerland) [2]. Therefore, Dr Bruni and his research group aimed to develop a risk score for the presence of SSc-ILD (the ILD-RISC score) to guide physicians in ordering both baseline and follow-up HRCTs.
For the identification of SSc-ILD, 13 variables were considered important: sex, age, disease duration from first non-Raynaud’s phenomenon sign or symptom, skin subset, presence of oesophageal symptoms, current or past digital ulcers, arthritis, smoking, increased inflammatory markers, New York Heart Association (NYHA) class, positive SSc-related autoantibodies, the percentage of forced vital capacity (FVC%), and the percentage of diffusing capacity for carbon monoxide (DLCO%).
The prediction model for ILD was developed from baseline visits of SSc patients in 6 European referral centres using multivariable logistic regression with backward selection. Of the 780 included patients, 533 (43% ILD) and 247 (48% ILD) were randomly assigned to the derivation and validation cohorts.
In the derivation cohort, a model including FVC%, DLCO%, digital ulcers, age, and SSc-related autoantibodies showed an OR of 133.9 (95% CI 53.4-335.9) for the presence of ILD on HRCT. An ILD-RISC score ≥0.3 showed comparable precision and accuracy in the derivation, validation, and longitudinal cohorts, with a sensitivity of 85.6% and specificity of 53.6%.
Among 819 patients with negative baseline HRCT, 170 (20.8%) developed ILD during a 3.8 ± 3.0 years follow-up. Longitudinally, in almost 50% of visits (n=914/1809), HRCT could be correctly skipped following an ILD-RISC score <0.3.
“We still recommend performing HRCT screening in all patients if the test is readily available and patients are willing to undergo it so as not to miss any patient with ILD. However, in situations where HRCT is unavailable, our ILD-RISC score supports the ability of HRCT to identify this complication. Most important, it may help to decide when to order HRCTs at follow-up, thus limiting unnecessary exams,” Dr Bruni explained.
A limitation of the score is its relatively low specificity, leading to a certain number of false positives.
“We are already working to improve the score further and continue to reduce the number of unnecessary HRCTs,” he concluded.
- Fischer A, et al. Open Access Rheumatol. 2019;11:283-307.
- Bruni M, et al. Developing a screening tool for the detection of interstitial lung disease in systemic sclerosis: the ILD-RISC risk score. 1526, ACR Convergence 2022, 10–14 November, Philadelphia, USA.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Early treatment: a key to improved outcomes in polyarticular JIA Next Article
Bruton’s tyrosine kinase inhibition: a novel treatment option for Sjögren’s syndrome? »
« Early treatment: a key to improved outcomes in polyarticular JIA Next Article
Bruton’s tyrosine kinase inhibition: a novel treatment option for Sjögren’s syndrome? »
Table of Contents: ACR 2022
Featured articles
Bruton’s tyrosine kinase inhibition: a novel treatment option for Sjögren’s syndrome?
Early treatment: a key to improved outcomes in polyarticular JIA
ACR 2022 Congress Round-Up
Glucocorticoids in rheumatic diseases: Is there a skeletal sparing dose?
Bimekizumab: Robust 1-year results in treating psoriatic arthritis
Stimulation of PD-1: a new concept to treat RA
Denosumab in erosive hand arthritis: Structure repair of interphalangeal joints seems possible
High retention rates after switching between infliximab biosimilars
New analysis assesses the safety of tofacitinib regarding extended MACE
Lack of vaccination results in a higher frequency of pre-term births in pregnant women with rheumatic disease and COVID-19
Ankylosing spondylitis: Combining biologics with NSAID does not imply reduced radiographic progression
Diet and exercise programme: a successful OA strategy in a community-based setting
Bruton’s tyrosine kinase inhibition: a novel treatment option for Sjögren’s syndrome?
A novel risk score helps identify interstitial lung disease in patients with systemic sclerosis
Early treatment: a key to improved outcomes in polyarticular JIA
TYK2 inhibition shows potential as a treatment for SLE
Belimumab efficacious in cutaneous lupus erythematosus
No increased cancer risk in patients with rheumatic diseases and prior malignancy treated with novel therapies
Related Articles
February 4, 2020
Sustained efficacy of monotherapy with upadacitinib after 48 weeks
September 23, 2022
Novel biomarkers enable personalised medicine in early RA
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com